SQUAWK/NEWS
Account
Theme
Account
Menu
Live News EQUITY FLASH L impact

Aptevo Says Mipletamig Combination Enabled 21% of AML Patients to Reach Stem Cell Transplant

The report describes a treatment outcome in frontline AML patients; no broader market impact is specified.

APVO

Related stories